title: Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test?
abstract: Colorectal cancer is the second leading cause of cancer death in industrialized nations, accounting for 10% of the total cancer burden with an individual lifetime risk of ~6% in the USA (Siegel et al. in CA Cancer J Clin 62:9-29, 2014, American Cancer Society in Colorectal cancer facts and figures 2011-2013. American Cancer Society, Atlanta, 2011, Siegel et al. in CA Cancer J Clin 61:212-236, 2011). Although numerous screening methods have been incorporated into guidelines for colorectal cancer screening, no guideline includes a noninvasive blood-based test as a recommended option.
authors: Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1466, Houston, TX, 77030, USA, rbresali@mdanderson.org.
authors: Robert S
authors: RS
authors: Bresalier
authors: Scott
authors: S
authors: Kopetz
authors: Dean E
authors: DE
authors: Brenner
mesh_terms: D015415:Biomarkers / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood / Q000175:diagnosis*; D006801:Humans; D007159:Immunologic Tests; D008403:Mass Screening / Q000379:methods*; D009780:Occult Blood
chemical_list: D015415:Biomarkers